Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia

Inclusion Criteria:

• Subjects enrolled in Study 169 that have no ongoing adverse events, which in theopinion of the Investigator are related to study treatment and that precludes themfrom receiving continuing therapy

• Completed Study 169, or completed all study visits up to and including Week 4 and inthe event of an early withdrawal after Week 4 have ≤15% reduction in TWSTRS totalscore at Week 4 compared to their baseline TWSTRS total score in the double-blindstudy, and in the Investigator's clinical judgment, would benefit from Dysport® for CD

Exclusion Criteria:

• Diagnosis of pure retrocollis or pure anterocollis

• Requirement for Botulinum Neurotoxin (BoNT) injection to site(s) for disorders otherthan CD and unable to avoid such treatment(s) for the duration of the study

• Known hypersensitivity to BoNT or related compounds, or any component in the studydrug formulation

• Allergy to cow's milk protein

• Myasthenia gravis, other disease of the neuromuscular junction or clinicallysignificant, persistent neuromuscular weakness, or disease or symptoms that couldinterfere with the TWSTRS scoring

• Total body weight <95 lbs (43.09 kg)

• Previous phenol injections to the neck muscles

• Previous myotomy or denervation surgery involving the neck or shoulder region or deepbrain stimulation to treat CD

• Cervical contracture that limited passive range of motion

• Physiotherapy initiated <4 weeks before study entry or expected to be initiated duringthe study

• Treatment with aminoglycoside antibiotics within 30 days prior to study treatment

• Current or expected requirement for concomitant medication that could interfere withthe evaluation of study treatment

• Pregnant and/or lactating females

• Females of childbearing potential with a positive prestudy urine pregnancy test (apositive urine pregnancy test could be confirmed by a serum pregnancy test at thediscretion of the investigator) and subjects, or their partners, who did not agree touse adequate contraception (hormonal or barrier method of birth control) prior toinjection of study treatment and for the duration of study participation.Nonchildbearing potential is defined as postmenopause for at least 1 year, surgicalsterilisation at least 3 months before entering the study, or hysterectomy

• Individuals who had family or employee relationship to study site staff or sponsorstaff involved in the conduct of the study

• Any medical condition that could, as judged by the investigator, compromise compliancewith the objectives and procedures of this protocol or preclude the administration ofBoNT, including swallowing and other respiratory abnormality.

• Subjects who were unable and/or unwilling to comply fully with the protocol and thestudy instructions, as judged by the investigator